Your browser is no longer supported. Please, upgrade your browser.
MBIO Mustang Bio, Inc. daily Stock Chart
Mustang Bio, Inc.
Index- P/E- EPS (ttm)-1.14 Insider Own1.10% Shs Outstand13.35M Perf Week105.23%
Market Cap83.84M Forward P/E- EPS next Y-1.59 Insider Trans- Shs Float- Perf Month57.79%
Income-30.70M PEG- EPS next Q-0.37 Inst Own9.10% Short Float- Perf Quarter89.73%
Sales- P/S- EPS this Y8.20% Inst Trans-2.02% Short Ratio0.66 Perf Half Y31.93%
Book/sh1.35 P/B4.65 EPS next Y0.70% ROA-58.70% Target Price18.00 Perf Year-36.31%
Cash/sh2.55 P/C2.46 EPS next 5Y- ROE-65.00% 52W Range2.18 - 10.20 Perf YTD113.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.43% Beta-
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin- 52W Low188.07% ATR0.83
Employees38 Current Ratio6.30 Sales Q/Q- Oper. Margin- RSI (14)76.90 Volatility28.47% 12.61%
OptionableYes Debt/Eq0.00 EPS Q/Q-91.10% Profit Margin- Rel Volume8.40 Prev Close5.64
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume681.75K Price6.28
Recom- SMA2083.38% SMA5061.42% SMA20032.73% Volume5,728,949 Change11.35%
Dec-21-17Initiated Oppenheimer Outperform $18
Apr-18-19 12:16PM  Mustang Bio News: MBIO Stock Skyrockets on New Bubble Boy Therapy InvestorPlace +112.03%
10:58AM  Why Mustang Bio Stock Is On Fire Today Motley Fool
09:54AM  Bubble Boy Biotech Soars 250 Percent After Cure Announcement Bloomberg
07:42AM  The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio Benzinga
07:00AM  Mustang Bio's stock soars to near 4-fold gain after deal to commercialize 'bubble boy' disease treatment MarketWatch
06:40AM  Behind the licensing deal for St. Jude's 'bubble boy' disease cure American City Business Journals
Apr-17-19 09:04PM  Stocks to watch: Unilever, Moneysupermarket, Mustang Bio, Indivior Financial Times -5.34%
05:01PM  St. Jude Childrens Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine GlobeNewswire
05:00PM  St. Jude develops cure for bubble boy disease American City Business Journals
Apr-09-19 08:30AM  Mustang Bio to Present at the World Orphan Drug Congress USA 2019 GlobeNewswire
Apr-01-19 09:00AM  Mustang Bio Announces $20 Million Venture Debt Financing Agreement with Horizon Technology Finance GlobeNewswire
Mar-18-19 07:30AM  Mustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Mar-13-19 08:30AM  Mustang Bio to Present at Oppenheimers 29th Annual Healthcare Conference GlobeNewswire
Feb-20-19 08:30AM  Mustang Bio and Nationwide Childrens Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme GlobeNewswire
Dec-20-18 12:22PM  Need To Know: Mustang Bio, Inc. (NASDAQ:MBIO) Insiders Have Been Buying Shares Simply Wall St.
08:30AM  Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm GlobeNewswire
Dec-17-18 09:40AM  MBIO: Mustang: A Steed on the Fast Track Zacks Small Cap Research
Nov-28-18 08:00AM  Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy GlobeNewswire
Nov-19-18 07:25AM  Investor Expectations to Drive Momentum within Lawson Products, Kingold Jewelry, Liberty Broadband, Mustang Bio, Artesian Resources, and MYnd Analytics Discovering Underlying Factors of Influence GlobeNewswire
Nov-13-18 04:20PM  Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Oct-30-18 08:00AM  Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope GlobeNewswire
Oct-16-18 02:52PM  What Investors Should Know About Mustang Bio Incs (NASDAQ:MBIO) Financial Strength Simply Wall St. +5.98%
Oct-15-18 08:00AM  Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer GlobeNewswire +6.83%
Oct-01-18 08:00AM  Mustang Bio to Present at 8th Annual Partnering Forum at Cell & Gene Meeting on the Mesa GlobeNewswire -5.71%
Sep-07-18 07:08AM  Mustang Bio Sees Hammer Chart Pattern: Time to Buy? Zacks
Sep-04-18 07:15AM  Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018 GlobeNewswire
Aug-30-18 08:00AM  Mustang Bio to Participate in September Investor Conferences GlobeNewswire
Aug-13-18 04:15PM  Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
08:00AM  Mustang Bio and St. Jude Childrens Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency GlobeNewswire
07:41AM  St. Jude and Mustang Bio enter into exclusive worldwide license agreement American City Business Journals
Aug-09-18 08:00AM  Mustang Bio to Present at 10th Annual Bioprocessing Summit GlobeNewswire
Aug-02-18 10:29AM  Special Report: Biotech incubator taps investors through in-house brokerage Reuters
09:55AM  Biotech incubator taps investors through in-house brokerage Reuters
Jul-19-18 08:30AM  Mustang Bio Completes Pre-IND Meeting with FDA for MB-102 (CD123 CAR T) GlobeNewswire
Jun-25-18 07:30AM  Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes GlobeNewswire
Jun-22-18 08:00AM  Mustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass. GlobeNewswire +5.39%
May-31-18 07:30AM  Mustang Bio to Present at June Investor Conferences GlobeNewswire
May-30-18 07:30AM  Mustang Bio Announces Preclinical Data on Potency of its CAR T Cells in Glioblastoma Published in JCI Insight GlobeNewswire
May-17-18 07:40AM  Mustang Bio, Inc. (MBIO) Enters Oversold Territory Zacks
May-14-18 05:30PM  Mustang Bio Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-27-18 08:43AM  Mustang Bio (MBIO) is Oversold: Can It Recover? Zacks
Apr-06-18 09:55AM  Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-04-18 08:00AM  Mustang Bio to Present at Biotech Innovations Conference GlobeNewswire
Mar-29-18 04:30PM  Mustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
Mar-19-18 07:45AM  Mustang Bio to Present at CAR-T Congress USA GlobeNewswire -6.01%
Mar-15-18 07:30AM  Mustang Bio Announces Key Leadership Appointments GlobeNewswire
Mar-13-18 07:45AM  Mustang Bio to Present at March Investor Conferences GlobeNewswire
Mar-12-18 07:45AM  Mustang Bio to Present at the 255th American Chemical Society National Meeting & Exposition GlobeNewswire
Feb-06-18 08:30AM  Mustang Bio to Participate in Immuno-Oncology Panel at BIO CEO & Investor Conference GlobeNewswire
Dec-14-17 07:30AM  Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 10, 2018 GlobeNewswire
Dec-11-17 04:30PM  Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial GlobeNewswire
04:30PM  Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-04-17 08:30AM  Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies GlobeNewswire
Nov-14-17 08:30AM  Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights GlobeNewswire -6.04%
08:30AM  Mustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller GlobeNewswire
Nov-01-17 09:05AM  Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting GlobeNewswire
Oct-31-17 07:30AM  Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain GlobeNewswire +17.62%
Oct-30-17 07:30AM  Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts GlobeNewswire +13.14%
Oct-11-17 07:30AM  Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma GlobeNewswire
Sep-14-17 08:00AM  Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies GlobeNewswire
Sep-05-17 07:30AM  Mustang Bio to Present at the CAR-TCR Summit 2017 GlobeNewswire
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase I/II clinical trials. The company also develops CD123, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; CD20 for immunotherapy of B-cell lymphomas; CS1, an NK cell receptor regulating immune functions; IL13Ra2 CAR T cell program for glioblastoma; HER2 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; and PSCA CAR T for prostate and pancreatic cancers. It has a license agreement with Harvard University for the treatment of cancer; Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.